Company momentum continues to build after FDA clearance of PrecisionTAVI, the first cleared predictive modeling technology for heart valve replacement
DUBLIN, OHIO, UNITED STATES, February 6, 2024 /EINPresswire.com/ — DASI Simulations, a medical technology start-up offering a novel AI-powered medical platforms to advance toward lifetime management and improved outcomes for structural heart interventions, has closed it $5 million convertible note round. The company has now surpassed $7 million in funds raised.
DASI will use the funds to continue to commercialize and extend its initial product, PrecisionTAVI, and launch new AI-driven products in the structural heart domain.